yahoo_financeOriginal article
Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial
Phase 2negativeNegative
AI Analysis
Summary
Novartis's investigational ALS drug failed in a mid-stage clinical trial, representing a significant setback for the company's neurology pipeline.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
ALS drug failed mid-stage trial
Importance:6/10
Sentiment:
-0.80
pipeline_setbackclinical_trial_failureALSneurology
Related Companies
Read the original article
Published by yahoo_finance on September 22, 2026 1:50 AM